🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against superbug strains of the bacteria, according to scientists.

An International Health Concern

Cases of gonorrhoea are increasing around the world, with figures suggesting over 82 million instances per year. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Public health authorities are deeply concerned about the surge in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, marketed under the name a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Data and Global Access

According to results detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which involves a dual-drug approach. The trial enrolled hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have expressed positive views. Having a easy-to-administer therapy like this is hailed as a "critical tool" for public health efforts. This is considered crucial to lessen the impact of the infection for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.